A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outco...

Autores
García Salinas, Rodrigo N.; Magri, Sebastián Juan; Ruta, Álvaro; Ruta, Santiago Oscar
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Objective. Limited data in Latin America exists regarding the efficacy of switches from original biologicals to biosimilars in real-life scenarios. Currently, no studies assess this switch using imaging. The objective of this study was to evaluate clinical, functional, ultrasonographic, and radiological responses in a group of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) switched from original adalimumab (oADA) to biosimilar (bADA) (GP2017). Methods. A prospective cohort study included diagnosed RA and PsA patients undergoing oADA treatment. At the baseline visit, blood analysis, X-rays, ultrasound, and an interview for sociodemographic and clinical data were conducted. Evaluators were unaware of each other’s data. Patients switched to bADA during follow-up and were assessed in the same program within 3 to 12 months post-switch (only including patients with all evaluations). Results. Out of 270 RA cohort patients, 35 met the criteria for complete pre- and post-control post-switch to bADA (GP2017), along with 15 PsA patients. The mean time between the switch and the second evaluation was 4.1 months (interquartile range 7). No statistical differences were observed in disease activity or functional capacity. Regarding imaging, no difference was found in Xray erosion number; however, ultrasonography revealed decreased power Doppler (PD) activity, but not grayscale changes. No differences in acute phase reactants, joint count, or patient visual analog scale were observed between controls. Conclusions. In this analysis of the switch between oADA and bADA, no differences were found in disease activity, functional capacity, or radiographic progression. Ultrasonography indicated improvement of PD findings.
Facultad de Ciencias Médicas
Materia
Ciencias Médicas
Adalimumab
Biosimilars
Rheumatoid arthritis
Psoriatic arthritis
Ultrasonography
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/193451

id SEDICI_23f912ab396f11479b3f8bd79710a161
oai_identifier_str oai:sedici.unlp.edu.ar:10915/193451
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomesGarcía Salinas, Rodrigo N.Magri, Sebastián JuanRuta, ÁlvaroRuta, Santiago OscarCiencias MédicasAdalimumabBiosimilarsRheumatoid arthritisPsoriatic arthritisUltrasonographyObjective. Limited data in Latin America exists regarding the efficacy of switches from original biologicals to biosimilars in real-life scenarios. Currently, no studies assess this switch using imaging. The objective of this study was to evaluate clinical, functional, ultrasonographic, and radiological responses in a group of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) switched from original adalimumab (oADA) to biosimilar (bADA) (GP2017). Methods. A prospective cohort study included diagnosed RA and PsA patients undergoing oADA treatment. At the baseline visit, blood analysis, X-rays, ultrasound, and an interview for sociodemographic and clinical data were conducted. Evaluators were unaware of each other’s data. Patients switched to bADA during follow-up and were assessed in the same program within 3 to 12 months post-switch (only including patients with all evaluations). Results. Out of 270 RA cohort patients, 35 met the criteria for complete pre- and post-control post-switch to bADA (GP2017), along with 15 PsA patients. The mean time between the switch and the second evaluation was 4.1 months (interquartile range 7). No statistical differences were observed in disease activity or functional capacity. Regarding imaging, no difference was found in Xray erosion number; however, ultrasonography revealed decreased power Doppler (PD) activity, but not grayscale changes. No differences in acute phase reactants, joint count, or patient visual analog scale were observed between controls. Conclusions. In this analysis of the switch between oADA and bADA, no differences were found in disease activity, functional capacity, or radiographic progression. Ultrasonography indicated improvement of PD findings.Facultad de Ciencias Médicas2025-05-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://doi.org/10.4081/reumatismo.2025.1748http://sedici.unlp.edu.ar/handle/10915/193451enginfo:eu-repo/semantics/altIdentifier/url/https://www.reumatismo.org/reuma/article/view/1748info:eu-repo/semantics/altIdentifier/issn/0048-7449info:eu-repo/semantics/altIdentifier/issn/2240-2683info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc/4.0/Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2026-04-23T11:56:08Zoai:sedici.unlp.edu.ar:10915/193451Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292026-04-23 11:56:08.615SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
title A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
spellingShingle A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
García Salinas, Rodrigo N.
Ciencias Médicas
Adalimumab
Biosimilars
Rheumatoid arthritis
Psoriatic arthritis
Ultrasonography
title_short A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
title_full A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
title_fullStr A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
title_full_unstemmed A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
title_sort A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
dc.creator.none.fl_str_mv García Salinas, Rodrigo N.
Magri, Sebastián Juan
Ruta, Álvaro
Ruta, Santiago Oscar
author García Salinas, Rodrigo N.
author_facet García Salinas, Rodrigo N.
Magri, Sebastián Juan
Ruta, Álvaro
Ruta, Santiago Oscar
author_role author
author2 Magri, Sebastián Juan
Ruta, Álvaro
Ruta, Santiago Oscar
author2_role author
author
author
dc.subject.none.fl_str_mv Ciencias Médicas
Adalimumab
Biosimilars
Rheumatoid arthritis
Psoriatic arthritis
Ultrasonography
topic Ciencias Médicas
Adalimumab
Biosimilars
Rheumatoid arthritis
Psoriatic arthritis
Ultrasonography
dc.description.none.fl_txt_mv Objective. Limited data in Latin America exists regarding the efficacy of switches from original biologicals to biosimilars in real-life scenarios. Currently, no studies assess this switch using imaging. The objective of this study was to evaluate clinical, functional, ultrasonographic, and radiological responses in a group of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) switched from original adalimumab (oADA) to biosimilar (bADA) (GP2017). Methods. A prospective cohort study included diagnosed RA and PsA patients undergoing oADA treatment. At the baseline visit, blood analysis, X-rays, ultrasound, and an interview for sociodemographic and clinical data were conducted. Evaluators were unaware of each other’s data. Patients switched to bADA during follow-up and were assessed in the same program within 3 to 12 months post-switch (only including patients with all evaluations). Results. Out of 270 RA cohort patients, 35 met the criteria for complete pre- and post-control post-switch to bADA (GP2017), along with 15 PsA patients. The mean time between the switch and the second evaluation was 4.1 months (interquartile range 7). No statistical differences were observed in disease activity or functional capacity. Regarding imaging, no difference was found in Xray erosion number; however, ultrasonography revealed decreased power Doppler (PD) activity, but not grayscale changes. No differences in acute phase reactants, joint count, or patient visual analog scale were observed between controls. Conclusions. In this analysis of the switch between oADA and bADA, no differences were found in disease activity, functional capacity, or radiographic progression. Ultrasonography indicated improvement of PD findings.
Facultad de Ciencias Médicas
description Objective. Limited data in Latin America exists regarding the efficacy of switches from original biologicals to biosimilars in real-life scenarios. Currently, no studies assess this switch using imaging. The objective of this study was to evaluate clinical, functional, ultrasonographic, and radiological responses in a group of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) switched from original adalimumab (oADA) to biosimilar (bADA) (GP2017). Methods. A prospective cohort study included diagnosed RA and PsA patients undergoing oADA treatment. At the baseline visit, blood analysis, X-rays, ultrasound, and an interview for sociodemographic and clinical data were conducted. Evaluators were unaware of each other’s data. Patients switched to bADA during follow-up and were assessed in the same program within 3 to 12 months post-switch (only including patients with all evaluations). Results. Out of 270 RA cohort patients, 35 met the criteria for complete pre- and post-control post-switch to bADA (GP2017), along with 15 PsA patients. The mean time between the switch and the second evaluation was 4.1 months (interquartile range 7). No statistical differences were observed in disease activity or functional capacity. Regarding imaging, no difference was found in Xray erosion number; however, ultrasonography revealed decreased power Doppler (PD) activity, but not grayscale changes. No differences in acute phase reactants, joint count, or patient visual analog scale were observed between controls. Conclusions. In this analysis of the switch between oADA and bADA, no differences were found in disease activity, functional capacity, or radiographic progression. Ultrasonography indicated improvement of PD findings.
publishDate 2025
dc.date.none.fl_str_mv 2025-05-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.4081/reumatismo.2025.1748
http://sedici.unlp.edu.ar/handle/10915/193451
url https://doi.org/10.4081/reumatismo.2025.1748
http://sedici.unlp.edu.ar/handle/10915/193451
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.reumatismo.org/reuma/article/view/1748
info:eu-repo/semantics/altIdentifier/issn/0048-7449
info:eu-repo/semantics/altIdentifier/issn/2240-2683
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc/4.0/
Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc/4.0/
Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1863367893616427008
score 13.05261